awmsg logo



aprepitant (EMEND®)


Reference No. 2937

Publication date:
27/07/2016


Appraisal information

aprepitant (EMEND®) 125 mg powder for oral suspension
aprepitant (EMEND®) 80 mg capsule
aprepitant (EMEND®) 125 mg capsule


Company: Merck Sharp & Dohme Ltd
BNF category: Central nervous system
NMG meeting date: 08/06/2016
AWMSG meeting date: 13/07/2016
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1816
Ministerial ratification: 26/07/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Aprepitant (EMEND®) is recommended as an option for use within NHS Wales for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients from the age of 6 months to less than 18 years old. Aprepitant is given as part of combination therapy.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download